患有痴呆症的人群中与RISPERIDONE相关的多种不良结果:个体参与者数据元分析
Hieu T Le1, Edward C Y Lau1, Christine Y Lu1,2,3
1Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Science Road, Camperdown, Sydney, NSW, 2006, Australia.
CNS drugs
|March 3, 2026
概括
在痴呆症患者中使用瑞斯佩里会增加脑血管和心血管事件的风险,特别是在治疗四周后. 识别高风险个体对于更安全的处方和尽量减少不良结果至关重要.
科学领域:
- 老年精神病学是一门精神病学专业.
- 临床药理学 临床药理学
- 神经科学是一个神经科学.
背景情况:
- 里斯佩里对痴呆症 (BPSD) 的行为和心理症状的疗效有限.
- 目前的指导方针建议短期使用 (12-16周) 由于不良事件.
- 需要了解长期风险和不利结果的预测因素.
研究的目的:
- 为了评估随着时间的推移在痴呆症患者中与RISPERIDONE相关的不良结果.
- 确定这些不良事件的关键预测因素.
- 为了更安全的处方策略,检查高风险子组.
主要方法:
- 一个对六项随机对照试验的个人参与者数据的元分析.
- 包括1009名接受Risperidone治疗的患者和712名接受安慰剂治疗的患者.
- 利用混合效应模型来分析不良结果,预测因素和子组差异.
主要成果:
- 里斯比显著增加了脑血管事件 (HR 4.11) 和主要心血管事件 (HR 2.00) 的风险,中位数发病时间约为4-5周.
- 昏昏欲睡是一致的;上呼吸道感染 (OR 2.31) 和额外金字塔症状 (OR 2.93) 在第4周后出现.
- 高龄,男性性别和基线心脏药物预测了严重的不良结果.
结论:
- 在痴呆症中,RISPERIDONE的大多数不良反应在治疗四周后就会显现出来.
- 评估基线风险因素对于减轻危害至关重要.
- 推个性化处方,可能以风险效益计算器为指导.
相关概念视频
Drug Dosing: Geriatric Patients
395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395
Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367
Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Dementia
687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


